Basal-like Breast cancer DNA copy number losses identify genes involved in genomic instability, response to therapy, and patient survival.
about
Comprehensive molecular portraits of human breast tumoursThe quiescent cellular state is Arf/p53-dependent and associated with H2AX downregulation and genome stabilityDifferential pathogenesis of lung adenocarcinoma subtypes involving sequence mutations, copy number, chromosomal instability, and methylationIdentifying in-trans process associated genes in breast cancer by integrated analysis of copy number and expression dataGenome instability in blood cells of a BRCA1+ breast cancer family.Transcriptomic classification of genetically engineered mouse models of breast cancer identifies human subtype counterparts.Remodeling of the methylation landscape in breast cancer metastasis.Using Drosophila melanogaster to identify chemotherapy toxicity genes.Micro-scale genomic DNA copy number aberrations as another means of mutagenesis in breast cancer.PARP1-driven poly-ADP-ribosylation regulates BRCA1 function in homologous recombination-mediated DNA repair.Triple negative breast cancers have a reduced expression of DNA repair genesAn integrated genomics approach identifies drivers of proliferation in luminal-subtype human breast cancer.Gene aberrations of RRM1 and RRM2B and outcome of advanced breast cancer after treatment with docetaxel with or without gemcitabine.Genomic analyses across six cancer types identify basal-like breast cancer as a unique molecular entity.Canine Mammary Tumours Are Affected by Frequent Copy Number Aberrations, including Amplification of MYC and Loss of PTENEnriched transcription factor signatures in triple negative breast cancer indicates possible targeted therapies with existing drugs.Cross-species DNA copy number analyses identifies multiple 1q21-q23 subtype-specific driver genes for breast cancerLoss of INPP4B causes a DNA repair defect through loss of BRCA1, ATM and ATR and can be targeted with PARP inhibitor treatment.Personalized medicine for patients with advanced cancer in the phase I program at MD Anderson: validation and landmark analyses.Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for germline pharmacogenetic studies.Identification of BRCA1-like triple-negative breast cancers by quantitative multiplex-ligation-dependent probe amplification (MLPA) analysis of BRCA1-associated chromosomal regions: a validation study.Tumor Evolution in Two Patients with Basal-like Breast Cancer: A Retrospective Genomics Study of Multiple MetastasesBasal-like breast cancer: molecular profiles, clinical features and survival outcomesBreast cancer regulated by Fringe.miR-548d-3p/TP53BP2 axis regulates the proliferation and apoptosis of breast cancer cells.Characterization of copy number alterations in a mouse model of fibrosis-associated hepatocellular carcinoma reveals concordance with human diseaseMet synergizes with p53 loss to induce mammary tumors that possess features of claudin-low breast cancer.Genomic profiling of murine mammary tumors identifies potential personalized drug targets for p53-deficient mammary cancers.Somatic copy number changes in DPYD are associated with lower risk of recurrence in triple-negative breast cancers.Germline and somatic KLLN alterations in breast cancer dysregulate G2 arrest.CCAT2, a novel long non-coding RNA in breast cancer: expression study and clinical correlations.Plk2 regulates mitotic spindle orientation and mammary gland developmentEglN2 contributes to triple negative breast tumorigenesis by functioning as a substrate for the FBW7 tumor suppressor.Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers.Metformin attenuates transforming growth factor beta (TGF-β) mediated oncogenesis in mesenchymal stem-like/claudin-low triple negative breast cancer.Amplification of SOX4 promotes PI3K/Akt signaling in human breast cancer.TP53 Mutations in Breast and Ovarian Cancer.Biological Subtypes of Triple-Negative Breast Cancer.Identification of Novel Breast Cancer Subtype-Specific Biomarkers by Integrating Genomics Analysis of DNA Copy Number Aberrations and miRNA-mRNA Dual Expression Profiling.Gene expression-based classifications of fibroadenomas and phyllodes tumours of the breast.
P2860
Q24630844-DB5AAE7E-E807-42D2-9BCA-5BE88A693BAFQ26864097-E26CE4C3-4FBC-4FE0-B51C-921B43FE4FAEQ28730029-CA4D0A4B-0E1B-4D58-85BF-0E0F2A5367C6Q30587051-5518B8BC-EEE7-440C-A232-7FABFD99D913Q33651926-758FD45C-7EE8-4F85-85F6-977F07E81EB2Q33742688-7E8ED476-D8A7-4C21-9887-02E96B10FC06Q33989254-2C76C670-9494-42A1-A39C-E12FFCE30F58Q34242959-163988B3-6C1B-4724-A339-F3C1D938D3F7Q34532230-E0B157B9-F299-47EF-A740-363ABC9E9883Q34644116-D871EB06-8745-4681-91E7-511994E04684Q34794035-40B135B8-CA7A-4026-899F-593771BAECE5Q34989075-496A9712-D5A4-4579-9BB6-B00AB16D5FC9Q35038441-CB06FB64-0687-4998-B1BE-6C482C4BF49DQ35079683-84C4F907-EEC6-487E-9509-8E5D6F2F0AEBQ35587062-154C7702-C01B-4B54-87CE-A4547DF5A31BQ35620990-DAEE1A43-6F3F-4B1C-B015-E19CC411CC77Q35816299-8EF01FE1-7179-4C89-81F2-A8BCB72D44A7Q35833060-3C3CE5CB-4B46-4EBD-ADC9-F447830C4679Q35899928-2D03C169-EA07-4D4D-B57E-D2C83B8522D9Q36047387-36710B3A-3B5C-40CD-A2B3-5002580F8D9CQ36166929-5F0FF49D-A30F-436A-9ACF-4397BC361BA1Q36214193-C34AE4A1-E8DC-4F75-9781-D6DB027432D6Q36325873-5B391E73-2784-49F7-8001-7FCAED7EFE88Q36352604-9BDCC654-5A55-4F34-8D91-FCAFBF0C131EQ36528396-F3A6FB76-3334-4BF3-8669-A2D2DB6E7E30Q36706884-502843D0-74CC-4D0A-B8F3-A4F8C39254EEQ36747465-5F29DB5C-9D6D-41D7-8A1A-CB9A3BE40EFDQ37120418-5F2F9F67-EA35-4A71-8F9F-A7F02F178CB2Q37279312-5BB5FB56-39FC-4B8F-8EBF-54498C74A3C9Q37380558-A9DD6BAE-BD70-4E7E-8F98-14E1F3B5ED11Q37381612-7C0B3B73-3C4D-4015-BA13-63B3E130AA8DQ37642893-DE64693B-25EA-45E8-905A-5CE6748C70A8Q37701681-C8B256CC-E299-4A55-8D82-D0AC8F799A60Q37718427-201FB57C-F269-4FBA-A688-A44049125144Q38790790-89C6B519-68C7-485C-90FC-6F30D26211CAQ38973005-E7278B04-0423-4FBF-8E77-BBCD7078FB0CQ38999130-FC4E1B8C-DF13-4973-B07C-797011989438Q39370768-334E6791-A130-4FAC-830E-F62ABFBAE5D4Q40037487-4FFF6BF5-2C48-4C94-BA79-8EBD82219999Q41136273-AB10B21C-548A-4BF1-A873-C2B55B333863
P2860
Basal-like Breast cancer DNA copy number losses identify genes involved in genomic instability, response to therapy, and patient survival.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Basal-like Breast cancer DNA c ...... therapy, and patient survival.
@ast
Basal-like Breast cancer DNA c ...... therapy, and patient survival.
@en
type
label
Basal-like Breast cancer DNA c ...... therapy, and patient survival.
@ast
Basal-like Breast cancer DNA c ...... therapy, and patient survival.
@en
prefLabel
Basal-like Breast cancer DNA c ...... therapy, and patient survival.
@ast
Basal-like Breast cancer DNA c ...... therapy, and patient survival.
@en
P2093
P2860
P50
P1476
Basal-like Breast cancer DNA c ...... therapy, and patient survival.
@en
P2093
Andrew Nobel
Andrey A Shabalin
Chika Nwachukwu
Dezheng Huo
Hann-Hsiang Chao
Joel S Parker
Tatyana Grushko
Victor J Weigman
Xiaping He
P2860
P2888
P304
P356
10.1007/S10549-011-1846-Y
P407
P577
2011-11-03T00:00:00Z